Autolus Therapeutics Files Routine 8-K on Jan 26

TL;DR

**Autolus Therapeutics filed a routine 8-K, no major news.**

AI Summary

Autolus Therapeutics plc filed an 8-K on January 26, 2024, reporting an event that occurred on January 22, 2024. This filing is a routine update under Regulation FD Disclosure and Financial Statements and Exhibits, indicating no major new financial or operational news. For investors, this means there's no immediate significant positive or negative catalyst disclosed in this specific filing that would drastically alter the stock's outlook, suggesting a period of stability or continued focus on existing developments.

Why It Matters

This filing is a standard procedural update, indicating no new material information that would immediately impact Autolus Therapeutics' stock price or investor sentiment. It's important for transparency but doesn't signal a change in the company's trajectory.

Risk Assessment

Risk Level: low — This 8-K is a standard disclosure with no new material information, posing minimal risk to investors.

Analyst Insight

A smart investor would view this filing as a non-event, confirming business as usual, and would continue to monitor for more substantive news like clinical trial results or financial reports.

Key Numbers

• $0.000042 — Par value per ordinary share (This is the nominal value of each ordinary share of Autolus Therapeutics plc.)

Key Players & Entities

• Autolus Therapeutics plc (company) — the registrant filing the 8-K
• The Nasdaq Global Select Market (company) — exchange where Autolus Therapeutics' shares are registered
• $0.000042 (dollar_amount) — par value per ordinary share

Forward-Looking Statements

• Autolus Therapeutics plc will continue to file routine disclosures without significant new material information in the near term. (Autolus Therapeutics plc) — high confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.000042 — resenting one ordinary share, par value $0.000042 per share AUTL The Nasdaq Global Selec

Filing Documents

• autl-20240122.htm (8-K) — 30KB
• pr22jan2024.htm (EX-99.1) — 8KB
• pr22jan2024001.jpg (GRAPHIC) — 321KB
• pr22jan2024002.jpg (GRAPHIC) — 50KB
• 0001730463-24-000007.txt ( ) — 675KB
• autl-20240122.xsd (EX-101.SCH) — 2KB
• autl-20240122_lab.xml (EX-101.LAB) — 23KB
• autl-20240122_pre.xml (EX-101.PRE) — 12KB
• autl-20240122_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On January 22, 2024, Autolus Therapeutics plc issued a press release announcing the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for obecabtagene autoleucel (obe-cel) for patients with relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL). Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of November 16, 2024, a standard review timeline consistent with recently approved CAR T therapies. The information contained in the presentation is furnished as Exhibit 99.1 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and is not incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits d) Exhibits Exhibit No. Description of Exhibit 99.1 Press release dated January 22, 2024

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTOLUS THERAPEUTICS PLC Dated: January 26, 2024 By: /s/Christian Itin Name: Christian Itin Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR